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Type 2 diabetesAbstract Background: Type 2 diabetes mellitus (DM) and metabolic syndrome (MetS) are partic-
ularly common medical disorders and are leading causes of morbidity and mortality worldwide.
Pulmonary function can be affected by DM.
Aim of the work: The study aimed to evaluate respiratory function tests and respiratory muscle
in patients with type 2 diabetes mellitus and correlated it with disease duration and control.
Subjects and methods: 45 male cases with type-2 diabetes were included as a study group; another
age-matched 45 cases were included as a control group. Clinical data, respiratory functions were
measured and correlated with disease duration and HA1c (diabetes control).
Results: Mean duration of diabetes mellitus was 7.62 ± 2.63 years, while mean HA1c was
7.48 ± 0.32.0. There was a signiﬁcant decrease of TLC, FVC, FEV1, PEFR, PImax and PEmax in
the study group, when compared to the control group. On the other hand, no signiﬁcant difference
was found between the two groups as regards FEV1/FVC. On the other hand, there was an inverse,
signiﬁcant correlation between HA1c and DM durations from one side and each of FVC, FEV1 and
PImax from the other side.
Conclusion: Patients with type-2 diabetes had a restrictive respiratory defect and glycemic levels
and duration of disease are probably major determinants of lung pathology. However, these ﬁnd-
ings require further validation in subsequent research.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Type 2 diabetes mellitus (DM) and metabolic syndrome
(MetS) are particularly common medical disorders and areleading causes of morbidity and mortality worldwide [1].
World Health Organization estimated that, more than 180 mil-
lion people worldwide are affected by the disease and expected
that this number will be doubled by the year 2030 [2].
Diabetes causes various microvascular complications
(e.g., retinopathy, nephropathy and neuropathy). These com-
plications could be attributed to the biochemical and structural
changes in basement membrane proteins in different organ sys-
tems. Chronic hyperglycemia leads to glycosylation of proteins
such as collagen and elastin with subsequent thickening of
Table 2 Respiratory function tests in studied subjects.
Variables Patients Controls t P value
TLC 3.56 ± 0.13 4.24 ± 0.14 23.14 <0.001*
FVC 75.04 ± 3.81 88.82 ± 4.95 14.78 <0.001*
FEV1 73.42 ± 3.77 87.02 ± 5.59 13.51 <0.001*
FEV1/FVC 97.84 ± 1.74 97.99 ± 3.57 0.23 0.81
PEFR 59.91 ± 8.32 78.35 ± 4.44 15.24 <0.001*
PImax 59.57 ± 3.41 66.86 ± 2.82 11.03 <0.001
*
PEmax 36.28 ± 1.96 73.80 ± 3.97 11.36 <0.001
*
* Statistically signiﬁcant.
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in alveoli may restrict lung volumes and capacities [3].
In another study, Weynand et al. (1999) found that alveolar
epithelial and endothelial capillary basal lamina was signiﬁ-
cantly thicker in diabetics than in control subjects [4].
Several studies have shown that diabetes mellitus is associ-
ated with reduced lung function, as well as respiratory muscle
weakness, and this relationship could be interpreted as demon-
strating the damaging effects of diabetes on the lung [5–8].
Pulmonary gas exchange occurs through the respiratory
membrane that includes the alveolar basement membrane,
interstitium and capillary endothelium. Any insult to the integ-
rity of alveolo-capillary membrane of the lung will affect the
alveolar gas exchange. Thus it can be hypothesized that alter-
ations in pulmonary function, especially diminished alveolar
gas exchange can occur in patients with diabetes mellitus [9].
Aim of the work
The study aimed to evaluate respiratory function tests and
respiratory muscle in patients with type 2 diabetes mellitus
and correlated it with disease duration and control.
Patients and methods
The present study included 45 diabetic male patients, on oral
hypoglycemic drugs. The diagnosis of diabetes was determined
according to WHO criteria as follows, fasting blood sugar
P126 mg/dl and 2 h post load glucose test P200 mg/dl [10].
They were recruited from the internal medicine department,
Al-Azhar Faculty of Medicine; new Damietta; during the per-
iod from January 2014 through May 2014. Another 45 healthy
male subjects, matched for age were included in the study as a
control group.
Exclusion criteria
 Patients diagnosed with cardiopulmonary diseases.
 Patients with any endocrinological disease other than diabe-
tes mellitus.
 Smokers.
Pulmonary function tests, including forced expiratory
maneuver parameters [forced vital capacity (FVC), force expi-
ratory volume in 1 s (FEV1), and peak expiratory ﬂow (PEF)],
gas dilution lung volumes (total lung capacity, functional
residual capacity, and residual volume), inspiratory muscle
strength (PImax), and expiratory muscle strength (PEmax) mea-
surements, were performed by a spirometer (MessgeraeteTable 1 Clinical characteristics of studied subjects.
Variables Patients
Age (years) 51.11 ± 6.16
Weight (kg) 70.11 ± 2.97
Height (m) 1.69 ± 0.013
BMI (kg/m2) 24.49 ± 0.81
Duration of DM (years) 7.62 ± 2.63
HA1c% 7.48 ± 0.32GhbH Germany). All these pulmonary function tests met the
American Thoracic Society criteria [11], and predicted values
used are those of the European Coal and Steel Community
[12].
For laboratory investigations, 2 ml of venous blood was
drawn in EDTA-pretreated tubes under complete aseptic
precautions. Blood glucose levels were estimated by the glu-
cose oxidase–peroxidase GOD/POD method and the glycated
hemoglobin (HbA1C) was determined by the immuno-inhibi-
tion method, both using Beckman Coulter auto-analyzer.
The study protocol was approved by the hospital’s ethics
committee for human studies, and written informed consent
was obtained from all subjects.
Statistical analysis of data
Data were collected, organized, tabulated and statistically
analyzed by statistical analysis with SPSS 16.0 version (SPSS
Inc, Chicago, USA). Quantitative data were expressed as
mean ± SD, while qualitative data were expressed as relative
frequency and percent distribution. Independent samples t-test
was used for quantitative normally distributed variables, while
Chi square was used for qualitative data. A P-value of <0.05
was regarded as statistically signiﬁcant.
Results
Results of the present study are depicted in Tables 1–3 and
Figs. 1 and 2. Table 1 reveals that, there was no signiﬁcant
difference between cases and controls as regards age, weight,
height or BMI; mean duration of diabetes mellitus in the study
group was 7.62 ± 2.63 years, while mean HA1c was 7.48 ±
0.32 (poor control). Table 2 shows that, there was a signiﬁcant
decrease of TLC, FVC, FEV1, PEFR, PImax and PEmax in the
study group, when compared to the control group. On the
other hand, no signiﬁcant difference was found betweenControls t P value
52.44 ± 4.69 1.15 0.25
69.40 ± 2.94 1.14 0.25
1.69 ± 0.018 0.39 0.69
24.20 ± 0.72 1.77 0.08
– – –
– – –
Figure 1 Correlation between FEV1 and d
Figure 2 Correlation between FV
Table 3 Correlation between HA1c and diabetes duration
with respiratory function in study group.
HA1C DM duration
r P r P
HA1C – – 0.64 <0.001*
DM duration 0.64 <0.001* – –
TLC 0.003 0.98 0.08 0.59
FVC 0.67 <0.001* 0.88 <0.001*
FEV1 0.56 <0.001* 0.78 <0.001*
FEV1/FVC 0.28 0.06 0.26 0.07
PEFR 0.07 0.64 0.02 0.89
PImax 0.036 0.013* 0.39 0.008*
PEmax 0.12 0.44 0.02 0.88
* Statistically signiﬁcant.
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reveal that, there was a signiﬁcant proportional correlation
between DM duration and HA1c concentration. On the other
hand, there was an inverse, signiﬁcant correlation between
HA1c and DM duration from one side and each of FVC,
FEV1 and PImax from the other side. These results indicated
that, pulmonary functions and respiratory muscle strength
were signiﬁcantly affected by diabetes duration and control.
With long duration and bad control, these functions are nega-
tively affected.
Discussion
The effects of diabetes on the respiratory functions were con-
troversial. Some studies showed that pulmonary functionsiabetes mellitus duration in study group.
E and HA1c in study group.
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authors suggested that predicted vital capacity, total lung
capacity, DLCO [14], and PImax [7] were lower in diabetic
patients. Spirometry parameters such as FVC% and FEV1%
were also found to be lower in patients with diabetes when
compared with non-diabetic patients [5,15].
Results of the present study were in agreement with
Anandhalakshmi et al. (2013) who reported that, it was evident
that the pulmonary functions were decreased in diabetic
individuals in comparison with age and sex matched non-
diabetic subjects [16]. Speciﬁcally, diabetics had a signiﬁcant
reduction in FVC, FEV1, PEFR, FIVC, PIF and TLC relative
to their matched normoglycemic comparison group. In addi-
tion, these results were similar to the observations made in
other studies which documented decreased pulmonary func-
tion in diabetics [17,18].
The decrease in FVC, FEV1 and normal value of (FEV1/
FVC) shows restrictive pattern of lung disease in the diabetics.
Similar ﬁndings were observed by Shah et al. (2013), Irfan et al.
(2011), and Kanya Kumari et al. (2011) [17,19,20]. There was
increased cross-linkage formation between polypeptides of col-
lagen in pulmonary connective tissue, which decreases FVC and
hence was responsible for restrictive respiratory defects [16].
In the present study there was a signiﬁcant decrease in
PEFR in diabetic subjects which is similar to other studies
[21,22]. This may be related to the poor mechanical properties
of the lung, like lung compliance and elastic recoil of lungs. In
addition, myopathic or neuropathic changes and alterations in
the bronchial reactivity affect respiratory muscles further
which impairs the endurance and efﬁciency of ventilatory
pump [23].
In patients with type-1 diabetes, Wanke and coworkers
(1991) found that maximal sniff esophageal and trans-
diaphragmatic pressures and VC were signiﬁcantly lower than
in the control group, and the reduction of VC in patients was
explained by the reduced capacity of the inspiratory muscles [7].
Barrett-Connor and Frette (1996) reported that FVC and
FEV1 were inversely related to duration of diabetes [24]. In
another study, Davis et al. (2000) revealed that lower lung vol-
umes and reduced airﬂow were related to glycemic control [25].
On the other hand, Fatih et al. (2010) did not ﬁnd any rela-
tion between pulmonary function and diabetes duration, or
control or with respiratory muscle strength and they suggested
that lower pulmonary function parameters in type 2 diabetes
were not correlated with duration of diabetes, fasting blood
glucose, or %HbA1c levels in the patient group. In diabetes,
pathophysiological mechanisms that have played the role in
micro-angiopathy cause damages in alveolar basement mem-
brane due to the presence of abundant connective tissue and
extensive microvascular circulation [8].
Studies conducted by Davis et al. (2004), and Mckeevear
et al. (2005), identiﬁed pulmonary functions like FVC, FEV1
were signiﬁcantly reduced in diabetics with poor glycemic con-
trol [15,26]. . Davis et al., identiﬁed that a strong predictor of
reduced lung function was the level of glycemic control and an
increase of 1% in mean HbA1c was associated with a decrease
of 4% in predicted forced vital capacity (FVC) and reduced
lung function was an independent predictor of all-cause mor-
tality with a 10% reduction in FEV1 associated with a 12%
increase in all-cause mortality [15].
Results of the present study are in contradiction to that
reported by Anandhalakshmi et al. (2013) who reported that,none of the pulmonary functions are signiﬁcantly different
between the two groups (cases with duration shorter and those
longer than 10 years) [16]. However, Barret-Connor et al.
(1996), found that FEV1 and FVC were low in diabetic cases,
who had diabetes for more than 10 years and in hyperglycemic,
which became more apparent with the increase in the duration
of diabetes. Our study shows that the duration of diabetes had
inﬂuenced lung functions [24].
In short, results of the present study revealed that, patients
with type-2 diabetes had a restrictive respiratory defect and
glycemic levels and duration of disease are probably major
determinants of lung pathology. However, these ﬁndings
require further validation in subsequent research.Conﬂict of interest
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